Literature DB >> 8625538

Modulation of complement-mediated immune damage by intravenous immune globulin.

M Basta1.   

Abstract

High-dose intravenous immune globulin (IVIG) exerts a beneficial effect in a variety of immune disorders. One possible underlying mechanism of this effect could be interference with the complement system. This conclusion was based on the results obtained in animal models of complement-mediated pathology, in vitro complement assays and studies on related human diseases. Clearance of IgM-sensitized erythrocytes was specifically suppressed by IVIG treatment. The same therapy prevented pulmonary endothelial cell lesions, the hallmark of Forssman shock, in 75% of animals. All control animals, either untreated or injected with control reagents, died within minutes following induction of Forssman shock. In vitro uptake of C3b and C4b complement fragments onto corpusculate immune complexes was significantly inhibited by IVIG. Studies that involved patients suffering from disorders with pathogenesis similar to animal models of complement-mediated immune injury fully supported the hypothesis that IVIG interacts with activated complement components and prevents their deposition on target cells. The author's results suggest that IVIG can be an effective modulator of inappropriate complement attack.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625538

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 3.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 5.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

6.  A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

Authors:  Hua Zhou; Henrik Olsen; Edward So; Emmanuel Mérigeon; Denis Rybin; Jane Owens; Gregory LaRosa; David S Block; Scott E Strome; Xiaoyu Zhang
Journal:  Blood Adv       Date:  2017-03-14

7.  Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.

Authors:  M Dantas; R S Costa; J E Barbosa; M S Graeff; W Sarti; I F De Carvalho
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

8.  Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death.

Authors:  Thiruma V Arumugam; Sung-Chun Tang; Justin D Lathia; Aiwu Cheng; Mohamed R Mughal; Srinivasulu Chigurupati; Tim Magnus; Sic L Chan; Dong-Gyu Jo; Xin Ouyang; David P Fairlie; Daniel N Granger; Alexander Vortmeyer; Milan Basta; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

9.  Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.

Authors:  J L Teeling; E R De Groot; A J Eerenberg; W K Bleeker; G Van Mierlo; L A Aarden; C E Hack
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.

Authors:  David A Loeffler; Lynnae M Smith; Andrea C Klaver; Heather A Brzezinski; Essie I Morrison; Mary P Coffey; Barbara A Steficek; Susan S Cook
Journal:  Comp Med       Date:  2012-02       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.